A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...

CRISPR Therapeutics (NASDAQ: CRSP) is a pioneering biotech company, but it isn't yet a profitable one. That's why its shares ...

Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...

The global cell therapy technologies market is set to grow from USD 4.41 billion in 2025 to USD 7.91 billion by 2030, ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

What happened next may become the most important medical story of the decade. In just six months, a team at Children’s ...

CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

The last time The Lancet Microbe featured an Editorial on CRISPR was in November 2020, to mark that year’s Nobel Prize in Chemistry, jointly awarded to Emmanuelle Charpentier and Jennifer A Doudna for ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct gene-editing experiments. The device, CRISPR-GPT, is an artificial intelligence lab ...